SCHEMBL2416233

SCHEMBL2416233

CCN(CCc1csc(SC(C)(C)C(=O)O)n1)c1ncc(-c2ccc(C(F)(F)F)cc2)cn1

nearest known ligand 0.40

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 2/20 0.40
PPARA Q07869 3/20 0.39
TP53 P04637 10/20 0.35
LMNA P02545 4/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 2/20 0.34
KDM4E B2RXH2 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PPARG P37231 2/20 0.33
PPARD Q03181 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12273187 0.89 SLC22A12 (0.38) SLC22A12PPARATP53LMNAMAPT
SCHEMBL12273012 0.89 SLC22A12 (0.41) SLC22A12PPARATP53LMNAPOLB
SCHEMBL2409270 0.89 PPARD (0.37) SLC22A12PPARAPPARD
Hydrochloric Acid SCHEMBL2414621 0.89 SLC22A12 (0.38) SLC22A12PPARATP53LMNAMAPT
Hydrochloric Acid SCHEMBL2414916 0.89 SLC22A12 (0.40) SLC22A12PPARATP53LMNAPOLB
SCHEMBL12273073 0.86 SLC22A12 (0.40) SLC22A12PPARATP53LMNAPOLB
Hydrochloric Acid SCHEMBL2410530 0.85 SLC22A12 (0.39) SLC22A12PPARATP53LMNAPOLB
SCHEMBL2412764 0.84 PPARA (0.40) SLC22A12PPARATP53LMNAPOLB
SCHEMBL12274122 0.84 SLC22A12 (0.43) SLC22A12PPARATP53LMNAPOLB
SCHEMBL12272769 0.84 SLC22A12 (0.42) SLC22A12PPARATP53LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG SLC22A12 920/4885PPARA 1/4885TP53 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.